Approved

Listen on Spotify
Listen on Apple Podcasts
Listen on YouTube
TABLE OF CONTENTS
(00:00:00) - Introduction
(00:04:40) - $50 of Dried Lizard Venom
(00:29:17) - Fax of Death
(00:43:04) - Sleeping Beauty Awakens
(00:52:07) - Carl Icahn Sends a Letter
(01:09:19) - Endgame
(01:13:40) - Postmortem & Playbook
CREDITS
Co-hosted by Alex Kesin and Matthew Pech 
Written, edited, and produced by Alex Kesin
Music: “Food” by nerowski
* Special thanks to the team at NFX for the use of their recording studio.
SOURCES
Last updated: January 2026
I. PRIMARY DOCUMENTS
FDA Regulatory Documents
Symlin (pramlintide acetate) - NDA 21-332
* Approval Letter & Package (March 16, 2005)
* Medical Review
* Statistical Review
* Clinical Pharmacology & Biopharmaceutics Review
* Administrative Documents & Correspondence
Byetta (exenatide) - NDA 21-773
* Approval Letter & Package (April 28, 2005)
* Medical Review
* Statistical Review
* Clinical Pharmacology & Biopharmaceutics Review
* Administrative Documents & Correspondence
Bydureon (exenatide ER) - NDA 22-200
* Approval Letter (January 27, 2012)
* Other Action Letters (Complete Response)
* Summary Review
* REMS
* Administrative Correspondence
SEC Filings & Financial Documents
* Amylin 2005 Results Press Release (Ex-99.1, 8-K)
* Amylin 2007 Results Press Release (Ex-99.1)
* Amylin 2011 Form 10-K (Net Product Sales)
* Carl Icahn SEC Filing (Schedule 13D)
Proxy Fight & Legal Documents
* Carl Icahn Letter to Amylin (April 15, 2009)
* Amylin Response to Icahn (April 20, 2009)
* Police Fund v. Bradbury (Amylin) Trial (May 4, 2009)
* Lilly Litigation Ruling (May 25, 2011)
II. ORAL HISTORY & INTERVIEWS
* Howard Greene Oral History (UCSD Library, October 8, 2008) - Primary source for Hybritech founding, Ted Greene’s background, and early Amylin history
III. NEWS & TRADE PRESS
2000
* “The Rumsfeld Resume” - CBS News (December 28, 2000) - Donald Rumsfeld’s board tenure at Amylin (1991-1996)
* “Roller Coasting” - Forbes (July 24, 2000) - Joe Cook narrative, J&J partnership collapse
2005
* “Investing for a Profit and a Daughter’s Health” - NYT (March 19, 2005) - Allen Andersson investment story, “tablecloth deal”
2006
* “Diabetics see hope (and weight loss) in new drug” - NYT (March 2, 2006) - “Lizzie” nickname, patient testimonials
* “4 Diabetes Drugs Are Seen Raising Hope and Profit” - NYT (June 22, 2006) - Manufacturing shortage, 400,000+ patients
* “Don’t kill off life-saving drugs” - Heritage Foundation (August 15, 2006) - Policy perspective on Byetta’s potential impact
* “Byetta Craze Is First Salvo in Promising New Line of Drugs” - diaTribe - ADA conference chaos, “one man cried”
2007
* Dr. John Eng Profile - Diabetes In Control (September 18, 2007) - Eng’s discovery story, patent struggles, Amylin vs. Lilly negotiations
2008
* Xenome/Amylin Partnership - BioSpace (February 5, 2008) - Venom peptide library partnership
2009
* Eastbourne Capital Sells Stake - San Diego Union-Tribune (October 10, 2009) - End of Eastbourne activist campaign
* Survey: Additional Diabetes Drugs Needed - Cardiovascular Business (December 21, 2009) - Market research on GLP-1 adoption
2012
* “FDA review accuses Amylin of withholding data” - FierceBiotech (June 26, 2012) - Bydureon approval controversy
IV. ACADEMIC & SCIENTIFIC SOURCES
* “Structural insights into multiplexed pharmacological actions of tirzepatide...” - Nature Communications (February 25, 2022) - Tirzepatide structure, exenatide C-terminus connection
* “Structural and dynamic features of cagrilintide binding...” - Nature Communications (April 10, 2025) - Cagrilintide/pramlintide structural relationship
* “If You Poison Us Do We Not Die?” - BYU Law Review (May 1, 2010) - Legal analysis of poison put provisions
* “How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments” - Historical overview of GLP-1 development
V. HARVARD BUSINESS SCHOOL CASES
* “Amylin Pharmaceuticals: Diabetes and Beyond” (December 9, 2008) - Authors: Richard G. Hamermesh, Rachel Gordon
* “Amylin Pharmaceuticals: Diabetes and Beyond” (November 2, 2012 revision) - Authors: Richard G. Hamermesh, Carin-Isabel Knoop
VI. CORPORATE DOCUMENTS & PRESENTATIONS
Amylin investor presentations from corporate IR archives. Specific slides referenced in the script are noted below.
Investor Presentations (Full Decks)
* 2006 R&D Day Presentation (PDF) - Phybrids platform, GIP mimetic program (slides 43, 46, 58-59)
* 2007 R&D Day Presentation (PDF) - Market sizing, obesity portfolio positioning (slides 14, 28, 29, 78)
* 2007 J.P. Morgan Healthcare Conference (PDF) - Symlin Pen timeline (slide 25)
* 2007 Lehman Brothers Healthcare Conference (PDF) - Investor overview and pipeline update
Individual Slide Presentations (HTML Archives)
* Early Corporate Presentation (WFVK) - Early-era company overview
* 2003 Headquarters Presentation - January 2003 corporate update
* ADA IR Presentation - American Diabetes Association investor materials
VII. ADDITIONAL REFERENCES
* Encyclopedia.com: Amylin Pharmaceuticals, Inc.
* Miami Serpentarium Laboratories (Gila monster venom source)
* Dan Bradbury (former Amylin CEO) - Vivani Board Profile - Now developing exenatide implant for weight loss
* Full-year 2008 results - FierceBiotech
VIII. PRIMARY SOURCE FIGURES
IX. ANALYSIS FIGURES


This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.approved.fm

What is Approved?

Life sciences, under the hood. Deep dives into the patent filings, regulatory gauntlets, and capital-risks that shape the business of biology.